ASCO 2014 Coverage

pCR Not a surrogate for relapse-free survival in TNBC BRCA1/2 mutation carriers

pCR Not a surrogate for relapse-free survival in TNBC BRCA1/2 mutation carriers

In patients with triple-negative breast cancer (TNBC) who are BRCA1/2 mutation carriers, pathologic complete response (pCR) is not a surrogate for relapse-free survival, in contrast to those with non-BRCA mutations.

Does Early Integration of Palliative Care and Cancer Treatment Benefit Patients?

Does Early Integration of Palliative Care and Cancer Treatment Benefit Patients?

Immediately integrating cancer treatment and palliative care might improve survival at 1 year in patients with advanced cancers, suggest findings from the ENABLE III randomized controlled trial, presented at the 2014 ASCO Annual Meeting.

Early palliative support for family caregivers reduces depression

Early palliative support for family caregivers reduces depression

Family members caring for patients with advanced cancer benefit from early initiation of phone-based training and support.

Less frequent zoledronic acid for bone metastases safe, effective

Less frequent zoledronic acid for bone metastases safe, effective

In patients with breast cancer who had previously received monthly intravenous bisphosphonate therapy for bone metastases for a year or longer, maintenance zoledronic acid administered every 12 weeks was noninferior to every 4 weeks.

Reduced-dose radiation safe for certain patients with low-risk HPV-positive oropharyngeal cancer

Reduced-dose radiation safe for certain patients with low-risk HPV-positive oropharyngeal cancer

Reduced-dose intensity-modulated radiotherapy after complete clinical responses to induction chemotherapy for operable stage III/IVA, human papillomavirus (HPV)-positive head and neck cancer appears to be safe and might improve patients' quality of life.

Adolescent and Young Adult Cancer Survivors Report Cognitive, Sexual Late Effects

Adolescent and Young Adult Cancer Survivors Report Cognitive, Sexual Late Effects

Adult and young adult cancer survivors face cognitive and sexual late effects from cancer and its treatment, according to data compiled from an online cancer survivorship care planning tool presented at the 2014 ASCO Annual Meeting.

No benefits from neoadjuvant gemcitabine + carboplatin + paclitaxel in nasopharyngeal cancer

No benefits from neoadjuvant gemcitabine + carboplatin + paclitaxel in nasopharyngeal cancer

Patients with locally advanced nasopharyngeal cancer (NPC) do not benefit from the addition of neoadjuvant gemcitabine, carboplatin, and paclitaxel (GCP) to cisplatin chemoradiation.

Docetaxel + ADT ups survival in metastatic prostate cancer

Docetaxel + ADT ups survival in metastatic prostate cancer

Upfront standard androgen deprivation therapy plus six cycles of docetaxel significantly improves overall survival compared with ADT alone in men with metastatic hormone-sensitive prostate cancer.

Baseline hypertension, ASIs affect hypertension, survival during VEGF inhibitor therapy

Baseline hypertension, ASIs affect hypertension, survival during VEGF inhibitor therapy

Baseline hypertension and BMI can affect worsening hypertension among patients administered vascular endothelial growth factor signaling pathway inhibitors, according to research presented at the 2014 ASCO Annual Meeting.

Safe to postpone ADT in men with asymptomatic prostate cancer and rising PSA levels

Safe to postpone ADT in men with asymptomatic prostate cancer and rising PSA levels

For the approximately 60,000 men in the United States with prostate cancer who are asymptomatic after radical primary treatment yet have a PSA relapse, it's safe to postpone androgen deprivation therapy, a study presented at the 2014 American Society of Clinical Oncology Annual Meeting concluded.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs